TITLE

Correlation between thromboembolic score and anteroposterior diameter of left atrium and left ventricle ejection fraction in patients with atrial fibrillation

AUTHOR(S)
Lazic, Snezana; Markovic, Sanja; Sipic, Maja; Lazic, Bratislav
PUB. DATE
September 2015
SOURCE
Cardiologia Croatica;Sep/Oct2015, Vol. 10 Issue 9/10, p28
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES : It is considered that atrial fibrillation (AF) is present among 0.4% of adult population. CHA2 DS2 -VASc score is used for stratification of thromboembolic risk. Systolic heart failure has significant thrombogenic potential in atrial fibrillation. Data from the literature on causal relationship between enlarged left atrium and thromboembolic risk in patients with AF are controversial.PATIENTS AND METHODS : The study analyzed 90 patients with atrial fibrillation. Exclusion criterion was AF in sepsis, acute myocarditis and pericarditis, in acute myocardial infarction, and postoperative AF. Methods used were standard 12-lead ECG, transthoracic echocardiogram and laboratory tests. The first group included 12 (13.3%) patients with valvular AF, while the second group included 78 (86.7%) patients with non-valvular AF. RESULTS : Anteroposterior diameter of the left atrium was 55.6±11.5 mm vs. 46.3±6.2 mm in the second group; p<0.001. Ejection fraction (EF, %) was 37.1±10.1% in the first group vs. 43.0±11.6% in the second group; p=0.102. CHA2 DS2 -VASc score was 4.0 (1.0-6.0) in the first group vs. 3.0 (0.0-7.0) in the second group; p=0.132. The correlation between CHA2 DS2 -VASc score and anteroposterior diameter of the left atrium among all patients (n=90) was not statistically significant (r=1.0; p=0.346). Significant negative correlation was found between CHA2 DS2 -VASc score and EF among all patients (r=-0.420; p<0.001). CONCLUSIONS : In our study, the anteroposterior diameter of left atrium was not a determining factor of thromboembolic risk. However, with increase of CHA2 DS2 -VASc score, there was a reduction of EF which favors AF and increase in thromboembolic risk.
ACCESSION #
110926548

 

Related Articles

  • Is mitral regurgitation a predictor of left atrial thrombosis in patients with atrial fibrillation? Golubić, Karlo; Angebrandt, Petra; Ivanac Vranešić, Irena; Palić, Romana; Šmalcelj, Anton // Cardiologia Croatica;Sep/Oct2015, Vol. 10 Issue 9/10, p13 

    AIMS: According to research published so far, severe mitral regurgitation (MR) is associated with reduced prevalence of left atrial thrombosis (LAT) in patients with atrial fibrillation (AF), while moderate MR doesn't seem to affect the rate of thromboembolic complications. 1,2 Our aim was to...

  • Clinical impact of quantitative left atrial vortex flow analysis in patients with atrial fibrillation: a comparison with invasive left atrial voltage mapping. Lee, Jung; Hong, Geu-Ru; Pak, Hui-Nam; Shim, Chi; Houle, Helene; Vannan, Mani; Kim, Minji; Chung, Namsik // International Journal of Cardiovascular Imaging;Aug2015, Vol. 31 Issue 6, p1139 

    Recently, left atrial (LA) vortex flow analysis using contrast transesophageal echocardiography (TEE) has been shown to be feasible and has demonstrated significant differences in vortex flow morphology and pulsatility between normal subjects and patients with atrial fibrillation (AF). However,...

  • Echo is warranted for atrial fib patients at high risk of thromboembolism. Alexander, Sidney // Modern Medicine;Jun98, Vol. 66 Issue 6, p60 

    Presents an abstract of the article `Transesophageal Echocardiographic Correlates of Thromboembolism in High-Risk Patients With Nonvalvular Atrial Fibrillation,' by the Stroke Prevention Atrial Fibrillation (SPAF) investigators from the `Annals of Internal Medicine' journal dated April 15, 1998.

  • Prevention of Thromboembolism in Atrial Fibrillation. Segal, Jodi B.; McNamara, Robert L.; Miller, Marlene R.; Kim, Nina; Goodman, Steven N.; Powe, Neil R.; Robinson, Karen A.; Bass, Eric B. // JGIM: Journal of General Internal Medicine;Jan2000, Vol. 15 Issue 1, p56 

    Focuses on preventing thromboembolism in patients with atrial fibrillation. Efficacy of warfarin in patients with the risk of stroke; Comparison on the patient's risk of stroke and hemorrhage; Use of aspirin in patients with lower risk of stroke.

  • The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation. Davidson, Thomas; Husberg, Magnus; Janzon, Magnus; Levin, Lars-Åke // JAFIB: Journal of Atrial Fibrillation;Feb2011, Vol. 2 Issue 4, p870 

    Aim: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. People with AF have a significantly increased risk of thromboembolic events, including stroke, and the main treatment is therefore aimed at preventing thromboembolic events via anticoagulation with warfarin or...

  • Risk Factors for New Thromboembolic Stroke in Older Atrial Fib Patients.  // Modern Medicine;Oct98, Vol. 66 Issue 10, p34 

    Discusses the abstract of the article `Risk factors for new thromboembolic stroke in patients ...62 years of age with chronic atrial fibrillation,' by W.S. Aronow, C. Ahn et al, published in the July 1, 1998 issue of the `American Journal of Cardiology' periodical.

  • Contrast enhanced transesophageal echocardiography in patients with atrial fibrillation referred to electrical cardioversion improves atrial thrombus detection and may reduce associated thromboembolic events. Jung, Philip H.; Mueller, Marisa; Schuhmann, Christoph; Eickhoff, Madeleine; Schneider, Philip; Seemueller, Gueler; Dutton, Raphael; Rieber, Johannes; Kääb, Stefan; Sohn, Hae-Young // Cardiovascular Ultrasound;2013, Vol. 11 Issue 1, p1 

    Aims: Transesophageal echocardiography (TEE) is the gold standard for the detection of thrombi in patients with atrial fibrillation (AF) before undergoing early electrical cardioversion (CV). However, TEE generates inconclusive results in a considerable number of patients. This study...

  • Stop anticoagulants cautiously.  // Reactions Weekly;3/17/2012, Issue 1393, p2 

    The article discusses research study being done on the link between discontinuation of anticoagulant therapy among atrial fibrillation patients and thromboembolism risk, referencing a study by T. B. Larsen et al., published in the February 6, 2012 issue of "Danish Pharmacovigilance Update."

  • Characteristics of non-valvular atrial fibrillation patients who benefit most from anticoagulation treatment. Yun-Li Xing; Qing Ma; Xiao-Ying Ma; Cui-Ying Wang; Zhen Zhou; Ying-Shuo Huang; Ying Sun // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 10, p18721 

    Objectives: The objective was to determine who will benefit most from oral anticoagulation (OAC) for nonvalvular atrial fibrillation (NVAF) patients aged ≥ 75 years. Background: It was unclear whether all of NVAF aged ≥ 75 should receive OAC. Methods: We recruited NVAF ≥ 75...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics